PTC Therapeutics
PTCT
PTCT
179 hedge funds and large institutions have $1.84B invested in PTC Therapeutics in 2023 Q3 according to their latest regulatory filings, with 23 funds opening new positions, 81 increasing their positions, 58 reducing their positions, and 46 closing their positions.
New
Increased
Maintained
Reduced
Closed
more repeat investments, than reductions
Existing positions increased: | Existing positions reduced:
less ownership
Funds ownership: →
less funds holding
Funds holding: →
less call options, than puts
Call options by funds: $ | Put options by funds: $
44% less capital invested
Capital invested by funds: $3.3B → $1.84B (-$1.47B)
50% less funds holding in top 10
Funds holding in top 10: 4 → 2 (-2)
50% less first-time investments, than exits
New positions opened: 23 | Existing positions closed: 46
Holders
179
Holding in Top 10
2
Calls
$8.48M
Puts
$10.7M
Top Buyers
| 1 | +$108M | |
| 2 | +$98.5M | |
| 3 | +$33.5M | |
| 4 |
GPP
Great Point Partners
Greenwich,
Connecticut
|
+$18.6M |
| 5 |
Vanguard Group
Malvern,
Pennsylvania
|
+$14.6M |
Top Sellers
| 1 | -$66.5M | |
| 2 | -$46.7M | |
| 3 | -$43.2M | |
| 4 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$36.2M |
| 5 |
Bank of New York Mellon
New York
|
-$23.9M |